molecular – Share Talk

Novacyt S.A. (AIM:NCYT) DHSC dispute update

Abm April 26, 2022

Paris, France and Camberley, UK – 26 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with

Novacyt S.A. (AIM:NCYT) Approval of COVID-19 test under CTDA legislation

Abm April 12, 2022

Approval of second direct-to-PCR COVID-19 test in the UK under CTDA legislation

Genedrive PLC (AIM:GDR) NICE issues Medtech Innovation Briefing

Abm March 29, 2022

NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test

Genedrive® MT-RNR1 ID Kit Product – Video

Abm March 25, 2022

World’s first point of care genetic test used to influence neonatal management in an acute setting and reduce aminoglycoside-induced hearing loss

Genedrive PLC (AIM:GDR) First NHS Deployments of Genedrive System for AIHL

Abm March 18, 2022

First NHS Deployments of the Genedrive® System for Antibiotic Induced Hearing Loss

Genedrive PLC (AIM: GDR) Update on Point of Care Covid Test

Abm February 23, 2022

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, provides an update on the progress being made on the Genedrive®COV19-ID kit, its rapid point of care molecular test for

Novacyt S.A. (AIM: NCYT) Approval of COVID-19 test under CTDA legislation

Abm February 17, 2022

Paris, France and Camberley, UK – 17 February 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s PROmate ® COVID-19 2G

Genedrive PLC (GDR.L) Investor Presentation

Abm February 4, 2022

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its interim results for the six months ended 31 December 2021 on Tuesday, 29 March 2022.